Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 595

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 6
Chunk 595
---
 of the end of the period for our fiscal years ended December 31, 2022, 2023 and 2024 was as follows: 
​

                      ​                          ​      ​     ​      ​     ​      ​  
-------------------------------------------------------------------------------------
​                                                      2024         2023         2022
By Function:                                              ​            ​            ​
Oncology/Immunology - Research and Development          893          903          958
Oncology/Immunology - Commercial                        771          927          880
Corporate Head Office and Other                         147          158          187
Total                                                 1,811        1,988        2,025
​
As of December 31, 2024, a total of 108 employees on our Oncology/Immunology research and development team have M.D. or Ph.D. degrees. Additionally, our Other Ventures joint venture Shanghai Hutchison Pharmaceuticals employed a total of 3,007 full time employees as of December 31, 2024, and no such employees are represented by labor unions and covered by collective bargaining agreements. To date, we have not experienced any strikes, labor disputes or industrial actions which had or would have a material effect on our business, and consider our relations with the union and employees to be good.
We recognize the importance of high-quality employees in sustaining market leadership. Salary and benefits are kept at competitive levels, while individual performance is rewarded within the general framework of the salary, bonus and incentive system of our company, which is reviewed annually. Employees are provided with a wide range of benefits that include medical coverage, provident funds and retirement plans and long service awards. We stress the importance of staff development and provides training programs on an ongoing basis. Employees are also encouraged to play an active role in community care activities.
E.    Share Ownership.
See Item 6.B. “Compensation” and Item 7 “Major Shareholders and Related Party Transactions.”
F.    Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation.
Not applicable.
​